海口市附近聊天的妇女-海口市附近聊天的妇女_首页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
Nuclear medicine industry
Your current position: home page >> Dongcheng nuclear medicine >>Nuclear medicine industry

1. Overview of nuclear medicine

"Isotope and radiation technology" and its application is an important milestone in the history of human civilization in the 20th century. Based on radionuclides and their labeled compounds, nuclear technology has been applied to the research, diagnosis and treatment of diseases, forming an important branch of modern medicine nuclear medicine. The clinical application of nuclear medicine mainly includes: in vivo diagnosis (radionuclide imaging and diagnostic drug Kit), in vivo treatment (radionuclide therapy) and in vitro analysis (radioimmunoassay).

 

 

2. Development of nuclear medicine industry

Worldwide, North America is the largest market for nuclear medicine and radiopharmaceuticals, followed by Europe and Asia. The Asia Pacific region is also the fastest growing market for nuclear medicine. According to the forecast of transparency, the global nuclear medicine market will reach 60 billion US dollars in 2018, among which the nuclide medicine market will reach about 13 billion US dollars, with an annual growth rate of 18.3%.

The radiopharmaceutical industry in China is still in its infancy. In 2013, the output value of radiation drugs in China was 2 billion yuan. The market of diagnostic drugs and therapeutic drugs accounted for 80% and 20% respectively. In recent years, with the progress of nuclear medicine in China and the increasing awareness of radioactive drugs by the state and the public, the domestic radiopharmaceutical industry has developed rapidly, and the sales revenue has increased by about 25% every year. It is estimated that the total domestic market will reach 10 billion yuan by 2020. The domestic radiopharmaceutical industry is mainly distributed in Chengdu, Beijing and Shanghai. The industrial scale of Chengdu and Beijing is equivalent, accounting for about 40% respectively.

In terms of hospitals, by the end of 2015, more than 800 hospitals had nuclear medicine departments, more than 600 medical institutions carried out radionuclide treatment, and more than 2000 medical institutions carried out radioimmunoassay.

In China, enterprises engaged in the production and business activities related to radioactive drugs need to register with relevant departments in strict accordance with the regulations on radiation protection of radioisotopes and radiation devices, do a good job in radiation protection management, and accept the radiation protection supervision of relevant departments. The qualifications that enterprises need to obtain include the production license of radioactive drugs, the business license of radioactive drugs, and the radiation safety license.

 

 

 

3. Clinical application of nuclear medicine

Different ranges of radiation emitted by radiopharmaceuticals are the basis of nuclear medicine diagnosis and treatment.

In terms of disease diagnosis, nuclear medicine is used for bone imaging, heart perfusion tomography, thyroid imaging, regional cerebral blood flow tomography, renal dynamic imaging, early diagnosis of Alzheimer's disease, and is one of the best means to diagnose and guide the treatment of three major difficult diseases of heart, brain and tumor. The combination of single photon emission tomography (PET) and SPECT (TC) was used to make accurate imaging of the lesions.

In terms of disease treatment, the classic radionuclide drugs are mainly used in the treatment of hyperthyroidism, rheumatoid arthritis, bone pain caused by tumor bone metastasis and so on. In recent years, radioisotopes with excellent properties such as [177Lu], yttrium [90Y], radium [223rallutetium] have been increasingly used in new drug research and clinical treatment, and radioisotopes are making significant contributions to improving national health care. With the deepening of the concept of precision medicine, monoclonal antibody based tumor targeted therapy (radioimmunotherapy) has become the focus of attention, and will play an important role in tumor treatment in the future.

 

contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
No.7, Changshan Development Zone, Shandong Province
Copyright 2014 copyright of Yantai Group Co., Ltd Lu ICP Bei 18035060-1